These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 15541329)

  • 1. Reducing PSAnxiety: The importance of noninvasive chronic disease management in prostate cancer detection and treatment.
    Wilt TJ; Partin MR
    Am J Med; 2004 Nov; 117(10):796-8. PubMed ID: 15541329
    [No Abstract]   [Full Text] [Related]  

  • 2. Prostate dilemmas. Early detection is forcing more men to weigh the difficult treatment options.
    Brink S
    US News World Rep; 2000 May; 128(20):66-7, 71-2, 74 passim. PubMed ID: 10947279
    [No Abstract]   [Full Text] [Related]  

  • 3. Expectant management as a treatment for early-stage prostate cancer.
    O'Rourke ME
    Oncology (Williston Park); 2008 Feb; 22(2 Suppl Nurse Ed):36-8. PubMed ID: 18431897
    [No Abstract]   [Full Text] [Related]  

  • 4. The impact of reducing the prostate-specific antigen threshold and including isoform reflex tests on the performance characteristics of a prostate-cancer detection programme.
    Roddam AW; Hamdy FC; Allen NE; Price CP;
    BJU Int; 2007 Sep; 100(3):514-7. PubMed ID: 17542987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of a suspicious prostate biopsy on patients' psychological, socio-behavioral, and medical care outcomes.
    Fowler FJ; Barry MJ; Walker-Corkery B; Caubet JF; Bates DW; Lee JM; Hauser A; McNaughton-Collins M
    J Gen Intern Med; 2006 Jul; 21(7):715-21. PubMed ID: 16808772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-specific antigen kinetics in localized and advanced prostate cancer.
    Fitzpatrick JM; Banu E; Oudard S
    BJU Int; 2009 Mar; 103(5):578-87. PubMed ID: 19210674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.
    Urba WJ; Nemunaitis J; Marshall F; Smith DC; Hege KM; Ma J; Nguyen M; Small EJ
    J Urol; 2008 Nov; 180(5):2011-7; discussion 2017-8. PubMed ID: 18801509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in case mix and treatment patterns in prostate cancer in Saskatchewan during the prostate specific antigen testing era.
    Tonita JM; Skarsgard D; Muhajarine N
    Cancer Causes Control; 2009 Mar; 20(2):201-9. PubMed ID: 18825504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance.
    Latini DM; Hart SL; Knight SJ; Cowan JE; Ross PL; Duchane J; Carroll PR;
    J Urol; 2007 Sep; 178(3 Pt 1):826-31; discussion 831-2. PubMed ID: 17632144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Men considering a hypothetical treatment for prostate cancer: a comparison to patients.
    Van Manen L; Feldman-Stewart D; Brundage MD
    Patient Educ Couns; 2006 Apr; 61(1):33-42. PubMed ID: 16257170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy.
    Choueiri TK; Dreicer R; Paciorek A; Carroll PR; Konety B
    J Urol; 2008 Mar; 179(3):906-10; discussion 910. PubMed ID: 18207194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extensive biopsies and transurethral prostate resection in men with previous negative biopsies and high or increasing prostate specific antigen.
    Ploussard G; Dubosq F; Boublil V; Allory Y; de la Taille A; Vordos D; Hoznek A; Abbou CC; Salomon L
    J Urol; 2009 Oct; 182(4):1342-9. PubMed ID: 19683310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do changes in a high serum prostate-specific antigen level and the free/total prostate-specific antigen ratio after antibiotic treatment rule out biopsy and the suspicion of cancer?
    Dirim A; Tekin MI; Koyluoglu E; Oguzulgen AI; Peskircioglu L; Ozkardes H
    Urol Int; 2009; 82(3):266-9. PubMed ID: 19440011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of clinically localized prostate cancer. Part I--observation or treatment?].
    Szelachowska J; Kornafel J; Gisterek I
    Pol Merkur Lekarski; 2006 Dec; 21(126):594-7. PubMed ID: 17405305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The detection rate of prostate cancer in different prostate-specific antigen (PSA) levels in Chinese men].
    Li M; Na YQ
    Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(1):16-8. PubMed ID: 18346372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Editorial comment on: predictive factors for progression in patients with clinical stage T1a prostate cancer in the PSA era.
    Scattoni V
    Eur Urol; 2008 Feb; 53(2):361. PubMed ID: 17611014
    [No Abstract]   [Full Text] [Related]  

  • 17. Editorial comment on: predictive factors for progression in patients with clinical stage T1a prostate cancer in the PSA era.
    Joniau S
    Eur Urol; 2008 Feb; 53(2):362. PubMed ID: 17611018
    [No Abstract]   [Full Text] [Related]  

  • 18. Use of prostate-specific antigen in the follow-up of patients with localized prostate cancer: results of a nationwide survey of urologists.
    Penson D; Moul J; Gandhi S; Newling D
    Urology; 2006 Jul; 68(1):80-4. PubMed ID: 16777198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using prostate-specific antigen screening and nomograms to assess risk and predict outcomes in the management of prostate cancer.
    Hammerer PG; Kattan MW; Mottet N; Prayer-Galetti T
    BJU Int; 2006 Jul; 98(1):11-9. PubMed ID: 16566811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prostatic cancer in Sweden 1998-2003. Drastic change of the disease panorama].
    Varenhorst E; Garmo H; Holmberg L; Stattin P; Johansson JE
    Lakartidningen; 2006 Feb 1-7; 103(5):285-8. PubMed ID: 16512566
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.